Your browser is no longer supported. Please, upgrade your browser.
Cardiff Oncology, Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own1.30% Shs Outstand39.55M Perf Week18.15%
Market Cap267.57M Forward P/E- EPS next Y-0.79 Insider Trans11.80% Shs Float38.87M Perf Month7.37%
Income-25.50M PEG- EPS next Q-0.24 Inst Own54.70% Short Float6.48% Perf Quarter-12.45%
Sales0.30M P/S891.89 EPS this Y61.30% Inst Trans-18.40% Short Ratio2.12 Perf Half Y-23.31%
Book/sh3.38 P/B1.81 EPS next Y-39.40% ROA-18.50% Target Price25.33 Perf Year-70.38%
Cash/sh3.07 P/C2.00 EPS next 5Y- ROE-19.40% 52W Range4.88 - 23.15 Perf YTD-65.98%
Dividend- P/FCF- EPS past 5Y57.20% ROI-14.90% 52W High-73.56% Beta1.65
Dividend %- Quick Ratio27.30 Sales past 5Y3.20% Gross Margin- 52W Low25.41% ATR0.44
Employees12 Current Ratio27.30 Sales Q/Q0.00% Oper. Margin- RSI (14)56.72 Volatility7.40% 7.40%
OptionableYes Debt/Eq0.00 EPS Q/Q9.30% Profit Margin- Rel Volume0.77 Prev Close5.51
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume1.19M Price6.12
Recom2.00 SMA2011.00% SMA501.66% SMA200-17.43% Volume966,362 Change11.07%
Dec-08-21Initiated Robert W. Baird Outperform $19
Aug-09-21Resumed Maxim Group Buy $30 → $20
Oct-22-20Initiated H.C. Wainwright Buy $27
Oct-08-20Initiated Piper Sandler Overweight $25
Dec-08-21 09:38AM  
Dec-03-21 08:30AM  
Nov-18-21 07:00AM  
Nov-14-21 07:18AM  
Nov-09-21 08:30AM  
Nov-04-21 04:15PM  
Oct-28-21 03:06PM  
Sep-30-21 08:36PM  
Sep-15-21 06:37AM  
Sep-08-21 04:00PM  
Sep-07-21 08:30AM  
Aug-25-21 08:15AM  
Aug-06-21 04:15AM  
Aug-05-21 04:15PM  
Aug-03-21 03:01PM  
Jul-12-21 08:00AM  
Jul-06-21 08:30AM  
Jun-28-21 08:30AM  
Jun-10-21 12:30PM  
Jun-08-21 08:30AM  
May-24-21 08:35AM  
May-20-21 08:30AM  
May-06-21 04:10PM  
Apr-23-21 11:39AM  
Apr-12-21 06:00AM  
Apr-10-21 08:30AM  
Apr-08-21 08:30AM  
Mar-25-21 01:41AM  
Mar-11-21 08:30AM  
Mar-10-21 04:30PM  
Mar-03-21 08:30AM  
Feb-27-21 02:23AM  
Feb-25-21 04:10PM  
Feb-24-21 08:30AM  
Feb-16-21 11:54AM  
Feb-11-21 08:00AM  
Feb-05-21 02:00AM  
Jan-28-21 11:28AM  
Jan-26-21 08:00AM  
Jan-19-21 08:52AM  
Jan-15-21 08:00AM  
Jan-13-21 03:18PM  
Jan-08-21 06:57AM  
Jan-07-21 04:20PM  
Jan-06-21 07:40AM  
Jan-05-21 06:59AM  
Dec-29-20 08:15AM  
Dec-27-20 12:10PM  
Dec-21-20 04:15PM  
Dec-18-20 05:50PM  
Dec-17-20 03:07PM  
Dec-16-20 02:40PM  
Dec-15-20 01:03PM  
Dec-14-20 08:45AM  
Dec-11-20 02:45PM  
Dec-09-20 05:57PM  
Dec-07-20 09:11AM  
Dec-06-20 08:30AM  
Dec-01-20 11:25PM  
Nov-23-20 08:30AM  
Nov-05-20 04:05PM  
Oct-25-20 09:19AM  
Oct-22-20 08:30AM  
Oct-20-20 08:30AM  
Oct-06-20 08:30AM  
Sep-30-20 12:14AM  
Sep-29-20 04:02PM  
Sep-17-20 08:00AM  
Sep-15-20 08:30AM  
Sep-14-20 08:30AM  
Aug-18-20 09:16AM  
Aug-11-20 04:15PM  
Aug-04-20 08:30AM  
Jul-30-20 08:30AM  
Jun-16-20 08:30AM  
Jun-15-20 08:30AM  
Jun-09-20 08:15AM  
May-29-20 08:30AM  
May-28-20 08:15AM  
May-27-20 08:15AM  
May-19-20 08:15AM  
May-13-20 08:15AM  
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PACE GARY WDirectorSep 21Buy6.7530,000202,500494,811Sep 22 05:54 PM
Levine James E.Chief Financial OfficerSep 10Buy6.4730,000194,00030,000Sep 13 08:12 AM
Markin Rodney SDirectorMar 26Buy10.322,90029,93323,879Mar 29 01:38 PM
PACE GARY WDirectorMar 23Buy10.2310,000102,300464,811Mar 24 10:27 AM
JACOB GARY SDirectorMar 23Buy10.422,37024,68921,922Mar 23 03:57 PM
Kelemen VickiExec. VP and COOMar 23Buy10.319609,8986,053Mar 23 02:30 PM
Erlander MarkChief Executive OfficerMar 23Buy10.349659,98014,481Mar 23 12:24 PM
BRANCACCIO JOHN PDirectorMar 22Buy10.953,00032,85012,260Mar 22 06:35 PM
Armitage James ODirectorMar 19Buy10.824,00043,27114,490May 27 05:14 PM
PACE GARY WDirectorMar 18Buy10.553,00031,660454,811Mar 19 11:34 AM
PACE GARY WDirectorMar 04Buy9.271,50013,898451,811Mar 04 08:46 PM
Kelemen VickiExec. VP and COOJan 02Option Exercise0.007005,124Jan 05 04:04 PM
Erlander MarkChief Executive OfficerJan 02Option Exercise0.00260013,629Jan 05 04:03 PM